tetano
Editor, Senior Moderator
J Clin Psychopharmacol
. 2023 Sep-Oct;43(5):411-416.
doi: 10.1097/JCP.0000000000001721. Epub 2023 Jun 23. Association Between Selective Serotonin Reuptake Inhibitors Prevalent Use and COVID-19-Related Mortality: A Retrospective Cohort Study
Pablo Ignacio Osores[SUP] 1 [/SUP], María Noelia Vivacqua[SUP] 1 [/SUP], Carolina Vazquez[SUP] 2 [/SUP], Sebastián Marciano[SUP] 3 [/SUP], Diego Hernán Giunta[SUP] 3 [/SUP], José Luis Faccioli[SUP] 1 [/SUP]
Affiliations
Purpose/background: Since the emergence of the coronavirus disease 2019 (COVID-19), many efforts have been made to prevent and to treat the disease. In this line, the anti-inflammatory effect of selective serotonin reuptake inhibitors (SSRI) as alternatives for treating chronic inflammatory diseases has been studied. There is previous evidence of the usefulness of these drugs for reducing COVID-19 impact.
Methods/procedures: We conducted a retrospective single-center cohort study of adult patients with a positive reverse transcriptase-polymerase chain reaction for COVID-19, evaluating the association between SSRI use and in-hospital mortality.
Findings/results: Of 1689 included patients, 182 (10.8%) were exposed to SSRI. A total of 291 patients died during the hospitalization, representing an in-hospital mortality of 17.2% (95% confidence interval [CI], 15.4%-19.0%): 44 (24.2%) of the exposed to SSRIs versus 247 (16.4%) of those not exposed to SSRIs (crude odds ratio [OR], 1.62; 95% CI, 1.12-2.34; P = 0.009). No independent effect of SSRIs on in-hospital mortality was found when applying either the inverse probability of treatment weighting (OR, 1.15; 95% CI, 0.71-1.89; P = 0.56) or with conventional multivariable analysis 0.81 (95 % CI: 0.28-2.31, P = 0.69).
Implications/conclusions: In the present retrospective study of patients hospitalized for COVID-19, prior use of SSRIs did not reduce mortality.
. 2023 Sep-Oct;43(5):411-416.
doi: 10.1097/JCP.0000000000001721. Epub 2023 Jun 23. Association Between Selective Serotonin Reuptake Inhibitors Prevalent Use and COVID-19-Related Mortality: A Retrospective Cohort Study
Pablo Ignacio Osores[SUP] 1 [/SUP], María Noelia Vivacqua[SUP] 1 [/SUP], Carolina Vazquez[SUP] 2 [/SUP], Sebastián Marciano[SUP] 3 [/SUP], Diego Hernán Giunta[SUP] 3 [/SUP], José Luis Faccioli[SUP] 1 [/SUP]
Affiliations
- PMID: 37683229
- DOI: 10.1097/JCP.0000000000001721
Purpose/background: Since the emergence of the coronavirus disease 2019 (COVID-19), many efforts have been made to prevent and to treat the disease. In this line, the anti-inflammatory effect of selective serotonin reuptake inhibitors (SSRI) as alternatives for treating chronic inflammatory diseases has been studied. There is previous evidence of the usefulness of these drugs for reducing COVID-19 impact.
Methods/procedures: We conducted a retrospective single-center cohort study of adult patients with a positive reverse transcriptase-polymerase chain reaction for COVID-19, evaluating the association between SSRI use and in-hospital mortality.
Findings/results: Of 1689 included patients, 182 (10.8%) were exposed to SSRI. A total of 291 patients died during the hospitalization, representing an in-hospital mortality of 17.2% (95% confidence interval [CI], 15.4%-19.0%): 44 (24.2%) of the exposed to SSRIs versus 247 (16.4%) of those not exposed to SSRIs (crude odds ratio [OR], 1.62; 95% CI, 1.12-2.34; P = 0.009). No independent effect of SSRIs on in-hospital mortality was found when applying either the inverse probability of treatment weighting (OR, 1.15; 95% CI, 0.71-1.89; P = 0.56) or with conventional multivariable analysis 0.81 (95 % CI: 0.28-2.31, P = 0.69).
Implications/conclusions: In the present retrospective study of patients hospitalized for COVID-19, prior use of SSRIs did not reduce mortality.